2023
Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial
Bhatt A, Kosiborod M, Claggett B, Miao Z, Vaduganathan M, Lam C, Hernandez A, Martinez F, Inzucchi S, Shah S, de Boer R, Jhund P, Desai A, Fang J, Han Y, Comin‐Colet J, Drożdż J, Vardeny O, Merkely B, Lindholm D, Peterson M, Langkilde A, McMurray J, Solomon S. Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. European Journal Of Heart Failure 2023, 25: 2177-2188. PMID: 37771274, DOI: 10.1002/ejhf.3043.Peer-Reviewed Original ResearchCOVID-19 diagnosisRisk of deathHeart failureEjection fractionPandemic onsetTrial participantsCOVID-19Death rateMajor hypoglycaemic eventsChronic heart failureTime of diagnosisCOVID-19 survivorsDiabetic ketoacidosisHypoglycaemic eventsClinical outcomesHF eventsCOVID-19 casesTreatment benefitClinical riskCardiovascular trialsDeath/DapagliflozinEvent ratesPatientsDiagnosisHeart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER
Butt J, Lu H, Kondo T, Bachus E, de Boer R, Inzucchi S, Jhund P, Kosiborod M, Lam C, Martinez F, Vaduganathan M, Solomon S, McMurray J. Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER. European Journal Of Heart Failure 2023, 25: 2078-2090. PMID: 37634087, DOI: 10.1002/ejhf.3000.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseModerate chronic obstructive pulmonary diseaseCOPD statusSafety of dapagliflozinObstructive pulmonary diseaseHeart failurePulmonary diseasePrimary outcomeEjection fractionWorse outcomesKansas City Cardiomyopathy Questionnaire scoreBenefit of dapagliflozinPre-specified analysisSevere pulmonary diseaseCardiovascular deathCause hospitalizationPrimary endpointTreatment discontinuationAdverse eventsClinical eventsQuestionnaire scoresPlaceboDapagliflozinPatientsKnown historyOutpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial
Chatur S, Vaduganathan M, Claggett B, Cunningham J, Docherty K, Desai A, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial. Circulation 2023, 148: 1735-1745. PMID: 37632455, PMCID: PMC10664793, DOI: 10.1161/circulationaha.123.066506.Peer-Reviewed Original ResearchConceptsUrgent HF visitsComposite end pointHeart failureHF hospitalizationHF visitsHF eventsFirst presentationCardiovascular deathEnd pointEjection fractionSubsequent mortalitySubsequent deathEjection fraction heart failurePrimary end pointCardiovascular causesClinical decompensationPrespecified analysisAmbulatory carePatientsClinical relevanceSentinel eventsHospitalizationDapagliflozinDeathVisitsEfficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure
Kondo T, Wang X, Yang M, Jhund P, Claggett B, Vaduganathan M, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Langkilde A, Petersson M, Zaozerska N, Bachus E, Solomon S, McMurray J. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. Journal Of The American College Of Cardiology 2023, 82: 1014-1026. PMID: 37610398, DOI: 10.1016/j.jacc.2023.05.056.Peer-Reviewed Original ResearchConceptsSafety of dapagliflozinHeart failurePrimary outcomeEjection fractionPatient-level pooled analysisBenefit of dapagliflozinEfficacy of dapagliflozinReduced ejection fractionEffect of dapagliflozinDAPA-HFCardiovascular deathClinical characteristicsDiscontinuation ratesPatient characteristicsPooled analysisDapagliflozinPatientsBackground treatmentEvent ratesInhibitor efficacyEfficacyGeographic regionsOutcomesTreatmentPrevious reportsDapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction
Butt J, Docherty K, Kosiborod M, Inzucchi S, Køber L, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Jhund P, McMurray J. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction. JACC Heart Failure 2023, 11: 1411-1423. PMID: 37318419, DOI: 10.1016/j.jchf.2023.04.016.Peer-Reviewed Original ResearchConceptsKansas City Cardiomyopathy QuestionnaireActivity limitation scoresEffect of dapagliflozinLimitation scoresSocial activity limitationsHeart failureActivity limitationsDAPA-HF trialReduced ejection fractionProportion of patientsActivity limitation domainLimitation domainEjection fractionPhysical functionChronic diseasesDapagliflozinPatientsHealth statusPlaceboMixed-effects modelsMonthsBaselineComplete dataScoresSocial limitations
2022
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan
Yang M, Butt J, Kondo T, Jering K, Docherty K, Jhund P, de Boer R, Claggett B, Desai A, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Langkilde A, Martinez F, Petersson M, Shah S, Vaduganathan M, Wilderäng U, Solomon S, McMurray J. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal Of Heart Failure 2022, 24: 2307-2319. PMID: 36342375, DOI: 10.1002/ejhf.2722.Peer-Reviewed Original ResearchConceptsAngiotensin receptor neprilysin inhibitorMineralocorticoid receptor antagonistsSafety of dapagliflozinHeart failureEjection fractionPrimary outcomeReceptor antagonistRecent guidelinesSodium-glucose cotransporter 2 inhibitorsLower systolic blood pressureBenefit of dapagliflozinPrior HF hospitalizationSacubitril/valsartanCotransporter 2 inhibitorsEffect of dapagliflozinSystolic blood pressureARNI therapyHF hospitalizationCardiovascular deathAdverse eventsHazard ratioBlood pressureSGLT2 inhibitorsPatientsDapagliflozin
2020
Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF
Kristensen S, Docherty K, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF. European Heart Journal 2020, 41: ehaa946.0939. DOI: 10.1093/ehjci/ehaa946.0939.Peer-Reviewed Original ResearchMineralocorticoid receptor antagonistsRisk of hyperkalaemiaReduced ejection fractionSevere hyperkalaemiaMild hyperkalaemiaDAPA-HFHazard ratioEjection fractionHeart failureMRA useSodium-glucose cotransporter 2 inhibitor dapagliflozinDAPA-HF studyHeart Failure TrialCox regression analysisLife-saving therapyInhibitor dapagliflozinFailure TrialAdverse outcomesReceptor antagonistHyperkalaemiaPatientsDapagliflozinTreatment assignmentHFrEFPlacebo